Comparative Pharmacology
Head-to-head clinical analysis: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus ORETIC.
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs ORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moexipril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing diuresis and reducing plasma volume.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
One tablet (7.5 mg moexipril / 12.5 mg hydrochlorothiazide or 15 mg moexipril / 25 mg hydrochlorothiazide) orally once daily.
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
Moexiprilat (active metabolite) terminal half-life is approximately 2–9 hours (mean ~9 hours in hypertension; prolonged in renal impairment). Hydrochlorothiazide terminal half-life is 6–15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: Twice-daily dosing may be needed for 24-hour BP control; renal impairment requires dose adjustment.
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Moexipril is eliminated primarily by renal excretion (about 50% as unchanged drug and metabolites) and biliary/fecal excretion (about 50%). Hydrochlorothiazide is eliminated largely unchanged by renal excretion (≥95% via glomerular filtration and tubular secretion).
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic